Seikagaku entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3™, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain.
VISCO-3 received FDA Premarket Approval in 4Q15. Zimmer Biomet and Seikagaku have partnered on U.S. sales of Seikagaku's Gel-One® single-injection viscosupplement since 2012. Seikagaku's SUPARTZ FX® 5-injection treatment is marketed by Bioventus.
Sources: Seikagaku Corporation; FDA.gov; ORTHOWORLD Inc.
Seikagaku entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3™, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain. VISCO-3 received FDA Premarket Approval in 4Q15. Zimmer Biomet and Seikagaku have partnered on U.S. sales of...
Seikagaku entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3™, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain.
VISCO-3 received FDA Premarket Approval in 4Q15. Zimmer Biomet and Seikagaku have partnered on U.S. sales of Seikagaku's Gel-One® single-injection viscosupplement since 2012. Seikagaku's SUPARTZ FX® 5-injection treatment is marketed by Bioventus.
Sources: Seikagaku Corporation; FDA.gov; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
